PCOS is now PMOS. Here's what actually changed.

If you woke up this week confused because every PCOS account you follow is suddenly typing PMOS, you're not the only one. On May 12, 2026, the international AE-PCOS Society and 56 partner organizations officially renamed the condition. PCOS is out. PMOS is in.

Same condition. Same symptoms. Same treatments. New name. And the new name matters more than it sounds.

What the new name actually stands for

PMOS is short for Polyendocrine Metabolic Ovarian Syndrome. Three words doing real work:

• Polyendocrine. It involves multiple hormone-producing glands, not just the ovaries. Adrenals, thyroid, hypothalamus, pituitary. The whole network.
• Metabolic. Insulin resistance is at the center for around 70% of women with the condition. It is not a footnote.
• Ovarian. The ovaries are still part of the story. Just no longer the headline.

The old name, Polycystic Ovary Syndrome, focused everything on one thing: cysts on the ovaries. Which turned out to be wrong.

The cysts were never really cysts

This is the part that should have been corrected years ago. What ultrasound has been calling "polycystic ovaries" are not actually cysts. They are arrested antral follicles — eggs that started maturing and then stalled because they never got the hormonal signal to release.

Research has confirmed there is no actual increase in abnormal cysts on the ovaries of women with the condition (Lancet, 2026). The name was based on what early ultrasounds appeared to show. The biology was different.

That misnomer did real damage. Women diagnosed with PCOS spent years thinking they had a cyst problem when they actually had a whole-body endocrine and metabolic problem. The treatment focus drifted toward the ovaries when the metabolic and endocrine root causes deserved equal attention.

Who renamed it, and why now

The rename came from the international AE-PCOS Society, led by Professor Helena Teede at Monash University and Professor Terhi Piltonen at Oulu. The process took 14 years and involved over 22,000 survey responses from patients and clinicians worldwide. Findings were published in The Lancet on May 12, 2026.

Professor Teede called it a "landmark moment." The Society for Endocrinology and 55 other patient and professional organizations co-signed the change.

The motivation was straightforward: the old name reduced a complex, lifelong endocrine condition to a misunderstanding about cysts. That contributed to delayed diagnoses, inadequate treatment, and a generation of women who were handed birth control and a shrug when what they actually needed was a metabolic and endocrine workup.

What changes for you right now

Honestly, less than you might think. The rename is symbolic in the short term, structural in the long term.

• Diagnostic criteria stay the same. Clinicians still use the Rotterdam criteria. Irregular cycles, signs of androgen excess, and polycystic ovarian morphology on ultrasound. Two out of three.
• Treatment stays the same. Lifestyle, inositol, metformin, GLP-1s, anti-androgens, fertility support. Nothing in your care plan changes.
• You will see both names in the clinic. A three-year transition period is now underway. Full adoption lands in the 2028 International Guideline update. Your doctor may use either name for the next two years and that is expected.
• The framing of your care should shift. Less ovaries-first. More whole-body. Insulin resistance, metabolic risk, and hormonal signaling deserve to be in the foreground of every PMOS conversation.

Why the framing matters

Names shape what gets investigated. For years, "polycystic ovary syndrome" pulled clinical attention toward gynecology and away from endocrinology and metabolism. That is why so many women with PMOS go undiagnosed until they try to conceive, or until type 2 diabetes shows up at age 35.

The new name makes it harder to ignore the bigger picture. Women with PMOS have around four times the lifetime risk of type 2 diabetes, higher rates of non-alcoholic fatty liver disease, elevated cardiovascular risk, and roughly three times the risk of anxiety and depression. None of that is about the ovaries.

The rename is the medical community admitting the old name made the condition look smaller than it is.

What to do this week

If you have a PCOS diagnosis on your chart, you have a PMOS diagnosis. Nothing to update at the pharmacy or the insurance company. But two things worth doing:

1. Ask your next clinical visit about the metabolic and endocrine workup. Fasting insulin, full lipid panel, free testosterone, DHEA-S, thyroid panel. Not all of these get ordered automatically. Now that the new name puts metabolism in the middle, you have language to ask for them.
2. Learn your own pattern. Whatever the name on the chart, the condition shows up differently in each body. The faster you see your own version of it, the more leverage you have on it. That is exactly what Balance App is for. Track meals, cycle, mood, sleep, energy. The patterns surface in days, not years.

The bottom line

PCOS becoming PMOS is not a rebrand. It is a correction. The condition was misnamed for decades, the consequences showed up in delayed diagnoses and undertreated metabolic risk, and the people who pushed for the change deserve credit for getting it done. Welcome to PMOS. Same fight. Better name.